However, men with higher PSA levels did show modest improvements in survival, suggesting that hormone therapy might be worthwhile for them. PSA (prostate-specific antigen) is produced by the prostate ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

Hormone treatment, also known as androgen deprivation therapy (ADT), is a cornerstone of treatment for advanced prostate cancer. Hormone treatment decreases prostate cancer growth by lowering ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Joe Biden’s recent diagnosis of "aggressive" prostate cancer has sparked concerns about how far the disease has advanced. The former president’s prostate cancer has been characterized by a Gleason ...

WASHINGTON — Former President Joe Biden is receiving radiation and hormone therapy as part of a new phase of treating the aggressive form of prostate cancer he was diagnosed with after leaving office, ...

Read more about the under-prescription of first-line treatments for erectile dysfunction in patients with prostate cancer.